Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein.

Erdheim-Chester disease is a rare non-langerhans systemic histiocytosis of unknown origin, associated with bone diseases and severe visceral complications. Therapies have been disappointing. A recombinant form of interleukin-1 receptor antagonist (anakinra) has been used in a few cases when usual treatment fails. We report a new case of successfully interleukin-1 receptor antagonist treatment in Erdheim-Chester disease.
AuthorsAudrey Courcoul, Emmanuelle Vignot, Roland Chapurlat
JournalJoint, bone, spine : revue du rhumatisme (Joint Bone Spine) Vol. 81 Issue 2 Pg. 175-7 (Mar 2014) ISSN: 1778-7254 [Electronic] France
PMID23953221 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2013 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
Chemical References
  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Antirheumatic Agents (therapeutic use)
  • Erdheim-Chester Disease (drug therapy)
  • Humans
  • Interleukin 1 Receptor Antagonist Protein (therapeutic use)
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: